Entrada Therapeutics just announced the successful completion of a $116 million Series B financing. Entrada is a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics. This company was started in part by our own, Professor, Dehua Pei.

To read the full article: https://www.entradatx.com/news/entrada-therapeutics-announces-closing-of-116-million-series-b-financing